共被期刊论文引用了1次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Seroprevalence of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)in patients with cancer and the impact of anti-tumor treatment on antibodies显示文摘Objective The aim of this study was to examine the seroprevalence of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)among patients with cancer and followed up changes in SARS-CoV-2-specific antibodies to explore the impact of anti-tumor treatment in patients.Methods Patients with cancer who visited the Outpatient Clinic of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China between March 9 and April 30,2020 were enrolled in this retrospective cohort study.SARS-CoV-2 immunoglobulin(Ig)G,IgM,and viral load at various time points during the disease course were determined.Results We examined the serological results of 779 patients with cancer.The overall seroprevalence(IgG-positive or IgM-positive)rate of SARS-CoV-2 was 3.4%.The probability of seropositivity was significantly higher in patients with gastric cancer than in those without gastric cancer(odds ratio:6.349,95%confidence interval:2.191–18.396).Follow-up data showed that SARS-CoV-2 IgM and IgG levels decreased and the polymerase chain reaction test result remained negative in seropositive patients with cancer.Conclusion This study investigated the seroprevalence of SARS-CoV-2 in coronavirus disease(COVID-19)-positive patients with cancer in Wuhan,China.The seropositivity in patients with cancer was lower than or similar to that in the general population.Irrespective of anti-tumor therapy,the levels of SARS-CoV-2 antibodies decreased in these patients.More studies are needed to better understand the impact of anti-tumor therapy on change in the levels of SARS-CoV-2 antibodies. | Bili Wu Bo Liu Xueyan Jiang Ye Yuan Wan Qin Kai Qin Qi Mei Li Zhang Huilan Zhang Guangyuan Hu Xianglin Yuan | 2021 | Oncology and Translational Medicine2021，7，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员